Loading...
XOSL
BGBIO
Market cap6mUSD
, Last price  
NOK
Name

Bergenbio ASA

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
46.98%
Rev. gr., 5y
-37.51%
Revenues
848k
+139.55%
598,0000002,335,0008,900,000601,000774,000389,000354,000848,000
Net income
-139m
L-26.85%
-57,780,000-72,107,000-129,799,000-182,208,000-191,747,000-199,387,000-257,061,000-309,417,000-298,609,000-190,401,000-139,282,000
CFO
-153m
L-31.92%
-53,715,000-62,902,000-124,314,000-168,109,000-186,706,000-184,145,000-234,290,000-303,340,000-288,231,000-225,101,000-153,242,000
Earnings
May 27, 2025

Profile

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
URL
https://www.bergenbio.com/
IPO date
Apr 07, 2017
Employees
28
Domiciled in
NO
Incorporated in
NO

Valuation

Title
NOK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
848
139.55%
354
-9.00%
389
-49.74%
Cost of revenue
87,691
107,786
8,340
Unusual Expense (Income)
NOPBT
(86,843)
(107,432)
(7,951)
NOPBT Margin
Operating Taxes
(3,513)
Tax Rate
NOPAT
(86,843)
(107,432)
(4,438)
Net income
(139,282)
-26.85%
(190,401)
-36.24%
(298,609)
-3.49%
Dividends
Dividend yield
Proceeds from repurchase of equity
138,874
262,048
3,218
BB yield
-48.13%
-65.86%
-0.49%
Debt
Debt current
418
Long-term debt
818
418
550
Deferred revenue
Other long-term liabilities
Net debt
(139,337)
(155,585)
(149,521)
Cash flow
Cash from operating activities
(153,242)
(225,101)
(288,231)
CAPEX
Cash from investing activities
3,688
3,055
3,248
Cash from financing activities
129,610
224,884
2,904
FCF
(87,666)
(107,820)
(3,290)
Balance
Cash
140,155
156,421
150,071
Long term investments
Excess cash
140,113
156,403
150,052
Stockholders' equity
61,106
79,635
8,866
Invested Capital
62,413
48,259
79,907
ROIC
ROCE
EV
Common stock shares outstanding
35,277
14,313
7,726
Price
8.18
-70.58%
27.80
-67.56%
85.70
-63.17%
Market cap
288,563
-27.48%
397,902
-39.90%
662,096
-62.88%
EV
149,226
242,317
512,575
EBITDA
(86,387)
(107,209)
(7,068)
EV/EBITDA
Interest
4,700
578
321
Interest/NOPBT